AstraZeneca

AstraZeneca, Bristol diabetes drug disappoints in key test

AstraZeneca, Bristol diabetes drug disappoints in key test

Reuters

AstraZeneca signs obesity and diabetes pact with NGM

AstraZeneca signs obesity and diabetes pact with NGM

Pharma Times, UK

Strong Product Pipelines Have Pharmaceutical Companies Poised for Growth

Strong Product Pipelines Have Pharmaceutical Companies Poised for Growth

Motley Fool

Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions

Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions

Yahoo/Fly on the Wall

Diabetes Drugs Under Scrutiny As FDA Considers Another Study

Diabetes Drugs Under Scrutiny As FDA Considers Another Study

Pharmalot

When It Comes To Biotech, Diversity Is Key

When It Comes To Biotech, Diversity Is Key

Seeking Alpha

5 Drugs Stocks Dragging The Industry Down

5 Drugs Stocks Dragging The Industry Down

TheStreet.com

AstraZeneca - Conducting Major Acquisitions

AstraZeneca - Conducting Major Acquisitions

Seeking Alpha

AstraZeneca to Pay Up to $1.15 Billion for Pearl

AstraZeneca to Pay Up to $1.15 Billion for Pearl

Bloomberg

AstraZeneca’s Acquisition of Omthera Pharma Is a Desperate Act

AstraZeneca’s Acquisition of Omthera Pharma Is a Desperate Act

Motley Fool